

Informatics Division

NeoGenomics oncology data services allow cancer researchers, as well as pharmaceutical and biotech companies, to access a rich set of de-identified, real-world clinical data to accelerate the advancement of personalized oncology care.

Established in 2020, NeoGenomics' Informatics division possesses one of the world's largest databases of real-world oncology diagnostic results, currently encompassing more than 1.6 million patient profiles and growing.

By leveraging data-driven insights, our customers are able to help advance their promising oncology-focused precision medicines, including through optimizing clinical trial design and increasing patient access to commercial and investigational agents and trials.

Our informatics offerings include:

- Clinical and Commercial Analytics
- Trial Design, Site Planning, and Clinical Trial Matching
- Data Licensing
- Image Analysis in Digital Pathology

Quick Facts

- Conducts more than 1 million cancer-related tests each year
- Tests over 435,000 patients each year
- Has over 68,000 unique active providers

Enabling Precision Oncology

In 2021, NeoGenomics further bolstered its' informatics offerings with the acquisition of Trapelo Health, an Information Technology company focused on precision oncology. The addition of Trapelo enhances our ability to provide customers with the information needed to answer difficult and complex questions related to precision oncology biomarker testing and treatment options.

Commitment to Patients

NeoGenomics is committed to connecting our patients with potentially life-altering and life-saving medicines as well as providing them with the ability to be part of clinical trials for promising new medicines.

